Courtagen's Mitochondrial DNA Sequencing Projects Could Lead to New Protein Array Tests | GenomeWeb

Variants discovered through sequencing of mitochondrial DNA could find their way onto Courtagen Life Sciences' protein array panels, according to the firm's chief scientific officer.

In particular, the company sees potential for such sequencing-informed, protein-based assays in mitochondrial disease testing, and has also considered the use of such panels in quality control testing for medical cannabis, Kevin McKernan told BioArray News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.